Clinical Trials
16 trialsNCT00742963 2025-05-13
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
ImmunoGenesis
Phase 1/2 Completed
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT01864538 2025-05-11
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ImmunoGenesis
Phase 2 Terminated
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT06782555 2025-01-21
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
ImmunoGenesis
Phase 1/2 Recruiting
NCT02255110 2018-12-14
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Merck KGaA, Darmstadt, Germany
Phase 2 Terminated
NCT01833546 2018-10-15
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03098160 2017-10-30
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Phase 1 Unknown
NCT02076230 2016-06-10
A Phase 1 TH-302 Mass Balance Trial
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01440088 2016-06-02
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Threshold Pharmaceuticals
Phase 3 Completed
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT02020226 2016-06-02
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00743379 2015-05-07
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1/2 Completed
NCT01149915 2015-05-07
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
Phase 1 Completed
NCT01381822 2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00495144 2012-07-27
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Completed